Kamada opened higher at $8.26, compared with its previous close of $8.13. In the last trading session, the stock traded between $8.12 and $8.35. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Kamada is now worth
$ 143.72
Giving a profit of
$ 43.72 (43.72%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.12%)
Day High
$8.35
Day Low
$8.12
Day Open
$8.26
Prev Close
$8.13
Volume
83,626
1W Return
9.27%
1M Return
3.39%
3M Return
14.45%
6M Return
-3.91%
1Y Return
15.01%
Fundamentals
Market Cap ($ Mn)
468
PE Ratio
21.76
PB Ratio
1.82
PEG Ratio
2.76
ROE
7.90%
ROCE
6.90%
EPS (TTM)
-
Investment Returns
1 Week
9.27%
1 Month
3.39%
3 Months
14.45%
6 Months
-3.91%
9 Months
-4.58%
Financials
Quarterly
All values in $ Mn
44.0
Mar 25
44.8
Jun 25
47.0
Sep 25
44.7
Dec 25
45.2
Mar 26
54.9
Jun 26
Updates
9Nov
Kamada Q3FY26 Results: EPS beats at $0.14, sales miss estimate
Q3FY26 EPS of $0.14 beat consensus estimate of $0.13 by 7.69%. Quarterly sales of $52.034 million missed analyst estimate of $52.506 million by 0.90%. Full-year FY26 revenue guidance raised to $205m-$208m, above consensus. Operating cash flow more than doubled YoY to $37.6 million for 9MFY26.
3 days ago
6Oct
Kamada launches two new biosimilars in Israel to expand portfolio
Kamada launched Ustekinumab-Kamada and Enoxaparin-Kamada in Israel. Existing biosimilar sales projected at ~$4 million in 2026. Portfolio revenue expected to reach ~$10 million by 2028. 2030 target includes 12 marketed products generating ~$20-25 million.
Kamada Ltd. announced a three-year agreement to supply normal source plasma to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue. Initial commercial sales are anticipated in the fourth quarter of 2026, utilizing FDA-approved collection centers in Houston and San Antonio with a planned capacity of 50,000 liters per year each.
3mo ago
13Jul
Kamada highlights CYTOGAM study results at ISHLT meeting
Kamada Ltd. highlighted results from an Investigator-Initiated Study at the 2026 ISHLT meeting indicating CYTOGAM may improve clinical outcomes and modulate immune responses in high-risk lung transplant recipients. The study, presented by Dr. Daniel Calabrese, found that patients receiving CMVIG prophylaxis had better outcomes and reduced activated innate immune cells. These findings align with a prior 2023 study and may support increased utilization of CYTOGAM.
